메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Smartee Launches Early Orthodontic Solutions for Children and Teens in Australia

SYDNEY, Sept. 2, 2025 -- Smartee Denti-Technology, a global leader in innovative clear aligner solutions, has officially launched its clear aligner products for children and teenagers in Australia. The product lines include Smartee Kinder and Smartee Teen, are designed to address the unique orthodontic challenges of growing patients at different developmental stages. Market Insights: Pediatric Orthodontics in Australia In Australia, pediatric orthodontic care is delivered through three main practitioner groups: orthodontic specialists, pediatric dentists, and general pra
- 김갑성 기자
- 2025-09-03 16:26
DeepQure Strengthens Clinical Leadership with Former SoniVie Executive Appointment

SEOUL, South Korea, Sept. 3, 2025 -- DeepQure, a company pioneering a paradigm shift in hypertension treatment, today announced the appointment of Jason G. Jones as Global Vice President of Clinical & Regulatory Affairs. Jason joins DeepQure from SoniVie, an Israeli company developing catheter-based intravascular ultrasound renal denervation (RDN) treatment that was acquired by Boston Scientific for $540 million in March 2025. At SoniVie, he led the global clinical development strategy and clinical operations activities at the company. Jason oversaw the completion of enrollment for
- 김갑성 기자
- 2025-09-03 10:52
US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

SHANGHAI and JERSEY CITY, N.J., Sept. 2, 2025 -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) has approved BILDYOS® (denosumab-nxxp) injection 60 mg/mL and BILPREVDA® (denosumab-nxxp) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.1,2 "The FDA approvals of BILDYOS and BILPREVDA mark a significant step toward expanding access to critical bone care treatments needed by millions of people in the US, inclu
- 김갑성 기자
- 2025-09-02 21:10
Seegene and Springer Nature Open Applications for 2025-2026 Nature Awards MDx Impact Grants

- The program focuses on antibiotic resistance in urinary tract infections (UTI-DR), with applications open until November 20; final awardees to be announced in August 2026- Selected researchers will receive up to USD 600,000 in research funding, along with access to Seegene's syndromic PCR assays, instruments, and software- Program aims to advance Seegene's Technology-Sharing Initiative and expand access to molecular diagnostics SEOUL, South Korea, Sept. 2, 2025 -- Seegene Inc., a global leader in molecular diagnostics, announced today the launch of the 20
- 김갑성 기자
- 2025-09-02 21:00
Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer's disease and Dementia Data

Neurophet's AI-based brain imaging analysis solutions to support global standardization of Alzheimer's and other dementia-related data Enhancing dementia research by integrating AI imaging solutions with real-world data platforms SEOUL, South Korea, Sept. 2, 2025 -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that it has signed a Memorandum of Understanding (MoU) with the International Registry for Alzheimer's Disease and Other Dementias Foundation (I
- 김갑성 기자
- 2025-09-02 21:00
Desilo to Launch "HARVEST™," Encrypted Data Collaboration Platform for Healthcare, in December

SEOUL, South Korea, Sept. 2, 2025 -- Desilo Inc., a privacy-technology startup specializing in cryptographic data collaboration, announced plans to launch its new healthcare platform, HARVEST™, this December. The platform is designed to allow medical institutions and pharmaceutical companies to collaborate on research without exposing sensitive patient data. Medical research often requires large, multi-institutional datasets, but privacy regulations and security risks have made data sharing difficult. According to IBM, the average cost of a healthcare data breach is $10.93 mill
- 김갑성 기자
- 2025-09-02 21:00
Lunit Selected as Exclusive AI Partner for Spain's Valencian Community Breast Screening Program

Milestone European deployment underscores growing global trust in Lunit's AI for population-wide breast cancer screening SEOUL, South Korea, Sept. 2, 2025 -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that its solutions have been selected as the exclusive AI tools for the breast cancer screening program of the Valencian Community, one of Spain's largest and most progressive healthcare regions. With a population of approximately 5 million, the Valencian Community is Spain's third-largest region by popul
- 김갑성 기자
- 2025-09-02 21:00
BON Announces Identification of Promising Weight-Managing Compounds from Tea via AI-Powered New Drug R&D Platform

XI'AN, China, Sept. 2, 2025 -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a groundbreaking identification of a class of natural polyphenolic compounds from a tea-derived product via its AI-Powered new drug research and development (R&D) platform. Preliminary tests demonstrate that these compounds exhibit significant activity in weight management, with key efficacy indicators outperforming current mainstream weight-managing drugs, injecting
- 황정호 기자
- 2025-09-02 20:30
ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions; marks new refractive and cataract milestones

ZEISS Medical Technology will showcase new ophthalmic innovations and market milestones at ESCRS from Sept. 12 - 15 in Copenhagen, Denmark: EFFICIENT, CONFIDENT DECISION MAKING: introducing AI-powered CIRRUS® PathFinder™ clinical support tool now CE mark approved; presenting a fully integrated diagnostic and SLT therapeutic solution for managing comorbid cataract/glaucoma patients. NEW STANDARDS IN SURGICAL EXCELLENCE: showcasing the DORC EVA NEXUS™ dual strategy surgical platform as part of ZEISS's expanding surgical workflow solutions. IMPROVED PREDICTABILITY OUTCOM
- 김갑성 기자
- 2025-09-02 20:00
SK bioscience Submits IND for Phase 3 Trial of 2-Dose Varicella Vaccine Reflecting Global Standard Shift

Approximately 800 children aged 12 months to 12 years in Korea and abroad, aiming for completion by 2027 Rising demand for 2-dose regimen as international standards amid projected global market growth to USD 6.3 billion by 3034 SKBS continues strategic R&D to enhance global vaccine competitiveness of its vaccine pipelines SEONGNAM, South Korea, Sept. 2, 2025 -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it has submitted an IND (Investigational New Drug application)
- 김갑성 기자
- 2025-09-02 19:00

이전

71 72 73 74 75 76 77 78 79 80

많이 본 기사

최근기사

2025-11-05_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 05일 07시 20분